CN1946714B - 用作多巴胺d3受体调节剂的氮杂二环(3.1.0)己烷衍生物 - Google Patents

用作多巴胺d3受体调节剂的氮杂二环(3.1.0)己烷衍生物 Download PDF

Info

Publication number
CN1946714B
CN1946714B CN2005800126155A CN200580012615A CN1946714B CN 1946714 B CN1946714 B CN 1946714B CN 2005800126155 A CN2005800126155 A CN 2005800126155A CN 200580012615 A CN200580012615 A CN 200580012615A CN 1946714 B CN1946714 B CN 1946714B
Authority
CN
China
Prior art keywords
methyl
propyl
azabicyclo
thio
triazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2005800126155A
Other languages
English (en)
Chinese (zh)
Other versions
CN1946714A (zh
Inventor
卢卡·阿里斯塔
乔尔吉奥·博纳诺米
安娜·M·卡佩利
费德里卡·达米亚尼
罗马诺·迪法比奥
加布里拉·金特尔
迪特尔·汉普里克特
法布里齐奥·米切利
卢卡·塔西
乔万纳·蒂德斯科
西尔维亚·特里尼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0403990A external-priority patent/GB0403990D0/en
Priority claimed from GB0404083A external-priority patent/GB0404083D0/en
Priority claimed from GB0417120A external-priority patent/GB0417120D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of CN1946714A publication Critical patent/CN1946714A/zh
Application granted granted Critical
Publication of CN1946714B publication Critical patent/CN1946714B/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Anesthesiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Otolaryngology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN2005800126155A 2004-02-23 2005-02-21 用作多巴胺d3受体调节剂的氮杂二环(3.1.0)己烷衍生物 Expired - Fee Related CN1946714B (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB0403990.5 2004-02-23
GB0403990A GB0403990D0 (en) 2004-02-23 2004-02-23 Compounds
GB0404083A GB0404083D0 (en) 2004-02-24 2004-02-24 Compounds
GB0404083.8 2004-02-24
GB0417120A GB0417120D0 (en) 2004-07-30 2004-07-30 Compounds
GB0417120.3 2004-07-30
PCT/EP2005/001940 WO2005080382A1 (en) 2004-02-23 2005-02-21 Azabicyclo (3.1.0) hexane derivatives useful as modulators of dopamine d3 receptors

Publications (2)

Publication Number Publication Date
CN1946714A CN1946714A (zh) 2007-04-11
CN1946714B true CN1946714B (zh) 2011-06-15

Family

ID=34890800

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2005800126155A Expired - Fee Related CN1946714B (zh) 2004-02-23 2005-02-21 用作多巴胺d3受体调节剂的氮杂二环(3.1.0)己烷衍生物

Country Status (25)

Country Link
US (3) US7855298B2 (https=)
EP (3) EP2070922B1 (https=)
JP (1) JP4960217B2 (https=)
KR (1) KR101143718B1 (https=)
CN (1) CN1946714B (https=)
AR (1) AR047890A1 (https=)
AT (3) ATE451364T1 (https=)
AU (2) AU2005215918C1 (https=)
BR (1) BRPI0507945A (https=)
CA (1) CA2557115C (https=)
CY (3) CY1109854T1 (https=)
DE (1) DE602005018190D1 (https=)
DK (3) DK2060570T3 (https=)
ES (2) ES2380990T3 (https=)
HR (3) HRP20100114T1 (https=)
IL (1) IL177184A0 (https=)
MA (1) MA28438B1 (https=)
NO (1) NO20064309L (https=)
PE (1) PE20051173A1 (https=)
PL (3) PL2060570T3 (https=)
PT (3) PT2070922E (https=)
RU (1) RU2434011C2 (https=)
SI (3) SI1745040T1 (https=)
TW (1) TW200538113A (https=)
WO (1) WO2005080382A1 (https=)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20051173A1 (es) * 2004-02-23 2006-02-14 Glaxo Group Ltd Compuestos azabiciclico (3.1.0) hexanos como moduladores de receptores de dopamina d3
US20070043100A1 (en) 2005-08-16 2007-02-22 Hagen Eric J Novel polymorphs of azabicyclohexane
GB0507602D0 (en) * 2005-04-14 2005-05-18 Glaxo Group Ltd Compounds
GB0507601D0 (en) * 2005-04-14 2005-05-18 Glaxo Group Ltd Compounds
GB0507680D0 (en) * 2005-04-15 2005-05-25 Glaxo Group Ltd Compounds
GB0512099D0 (en) * 2005-06-14 2005-07-20 Glaxo Group Ltd Compounds
WO2006133945A1 (en) 2005-06-14 2006-12-21 Glaxo Group Limited Novel compounds
WO2007006117A1 (en) * 2005-07-13 2007-01-18 Nicogen Inc. Novel cyp2a6 inhibitors
NZ592836A (en) * 2005-07-27 2013-01-25 Dov Pharmaceutical Inc Novel 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders
GB0517191D0 (en) * 2005-08-22 2005-09-28 Glaxo Group Ltd Compounds
GB0517187D0 (en) * 2005-08-22 2005-09-28 Glaxo Group Ltd Compounds
WO2007022933A1 (en) * 2005-08-22 2007-03-01 Glaxo Group Limited Triazole derivatives as modulators of dopamine d3 receptors
GB0517193D0 (en) * 2005-08-22 2005-09-28 Glaxo Group Ltd Novel use
GB0517175D0 (en) * 2005-08-22 2005-09-28 Glaxo Group Ltd Compounds
AR060237A1 (es) * 2006-04-03 2008-06-04 Glaxo Group Ltd Compuesto de 3-azabiciclo[3.1.0]hexano como moduladores del receptor de dopamina d3, su uso para la preparacion de un medicamento para el tratamiento de afecciones psicoticas y composicion farmaceutica que lo comprende.
GB0703387D0 (en) * 2007-02-21 2007-03-28 Glaxo Group Ltd Novel compounds
GB0607899D0 (en) * 2006-04-03 2006-05-31 Glaxo Group Ltd Process for preparing heterocyclic derivatives
US8222266B2 (en) * 2006-04-03 2012-07-17 Glaxo Group Limited Azabicyclo [3.1.0] hexyl derivatives as modulators of dopamine D3 receptors
US8163927B2 (en) * 2006-04-03 2012-04-24 Glaxo Group Limited Azabicyclo [3.1.0] hexane derivatives as modulators of dopamine D3 receptors
GB0608452D0 (en) * 2006-04-27 2006-06-07 Glaxo Group Ltd Novel compounds
US20080045725A1 (en) 2006-04-28 2008-02-21 Murry Jerry A Process For The Synthesis of (+) And (-)-1-(3,4-Dichlorophenyl)-3-Azabicyclo[3.1.0]Hexane
GB0616574D0 (en) * 2006-08-21 2006-09-27 Glaxo Group Ltd Compounds
US8138377B2 (en) 2006-11-07 2012-03-20 Dov Pharmaceutical, Inc. Arylbicyclo[3.1.0]hexylamines and methods and compositions for their preparation and use
US20090069374A1 (en) * 2007-06-06 2009-03-12 Phil Skolnick Novel 1-Heteroaryl-3-Azabicyclo[3.1.0]Hexanes, Methods For Their Preparation And Their Use As Medicaments
US9133159B2 (en) 2007-06-06 2015-09-15 Neurovance, Inc. 1-heteroaryl-3-azabicyclo[3.1.0]hexanes, methods for their preparation and their use as medicaments
GB0719235D0 (en) * 2007-10-02 2007-11-14 Glaxo Group Ltd Novel compounds
GB0719234D0 (en) * 2007-10-02 2007-11-14 Glaxo Group Ltd Novel compounds
CN102816106A (zh) 2008-06-24 2012-12-12 默沙东公司 用于制备基本上立体异构纯的稠合二环脯氨酸化合物的生物催化方法
US8536185B2 (en) 2008-09-22 2013-09-17 Cayman Chemical Company, Incorporated Multiheteroaryl compounds as inhibitors of H-PGDS and their use for treating prostaglandin D2 mediated diseases
BR112012000657A2 (pt) 2009-06-26 2016-11-16 Panacea Biotec Ltd novos azabicilohexanos
US20140206740A1 (en) 2011-07-30 2014-07-24 Neurovance, Inc. Use Of (1R,5S)-(+)-(Napthalen-2-yl)-3-Azabicyclo[3.1.0]Hexane In The Treatment Of Conditions Affected By Monoamine Neurotransmitters
US20160279098A1 (en) * 2013-11-11 2016-09-29 Euthymics Bioscience, Inc. Novel methods
HK1250029A1 (zh) 2015-08-05 2018-11-23 Indivior Uk Limited 具有双环结构的多巴胺d3受体拮抗剂
JP7250405B2 (ja) 2018-01-26 2023-04-03 塩野義製薬株式会社 ドーパミンｄ３受容体拮抗作用を有する環式化合物
CN116113627B (zh) 2020-06-22 2025-06-03 科赛普特治疗公司 季吲哚糖皮质激素受体拮抗剂
US12115154B2 (en) 2020-12-16 2024-10-15 Srx Cardio, Llc Compounds for the modulation of proprotein convertase subtilisin/kexin type 9 (PCSK9)
IL313667A (en) 2021-12-21 2024-08-01 Corcept Therapeutics Inc Glucocorticoid receptor antagonists INDAZOL CYCLES
CA3243549A1 (en) 2021-12-21 2023-06-29 Corcept Therapeutics Incorporated INDAZOLE PIPERAZINE-BASED GLUCOCORTICOID RECEPTOR ANTAGONISTS

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI274750B (en) * 1999-01-12 2007-03-01 Abbott Gmbh & Co Kg Triazole compounds showing high affinity to dopamine D3 receptor and pharmaceutical composition comprising the same
GB0015562D0 (en) * 2000-06-23 2000-08-16 Pfizer Ltd Heterocycles
JP4272423B2 (ja) 2000-11-14 2009-06-03 スミスクライン ビーチャム ピー エル シー ドーパミンｄ３受容体のモジュレーターとして有用なテトラヒドロベンズアゼピン誘導体（抗精神病剤）
US6569887B2 (en) * 2001-08-24 2003-05-27 Dov Pharmaceuticals Inc. (−)-1-(3,4-Dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake
EP1440059B1 (en) 2001-10-22 2008-04-16 Pfizer Products Inc. 3-azabicyclo(3.1.0)hexane derivatives as opioid receptor antagonists
IL166510A0 (en) * 2002-08-09 2006-01-15 Nps Pharma Inc 1,2,4"oxadiazole as modulators of metabotropic glutamate receptor-5
PE20051173A1 (es) * 2004-02-23 2006-02-14 Glaxo Group Ltd Compuestos azabiciclico (3.1.0) hexanos como moduladores de receptores de dopamina d3
GB0507601D0 (en) * 2005-04-14 2005-05-18 Glaxo Group Ltd Compounds
GB0507602D0 (en) * 2005-04-14 2005-05-18 Glaxo Group Ltd Compounds
GB0507680D0 (en) * 2005-04-15 2005-05-25 Glaxo Group Ltd Compounds
WO2006133945A1 (en) * 2005-06-14 2006-12-21 Glaxo Group Limited Novel compounds
GB0517175D0 (en) * 2005-08-22 2005-09-28 Glaxo Group Ltd Compounds
GB0517191D0 (en) * 2005-08-22 2005-09-28 Glaxo Group Ltd Compounds
GB0517193D0 (en) * 2005-08-22 2005-09-28 Glaxo Group Ltd Novel use
WO2007022933A1 (en) * 2005-08-22 2007-03-01 Glaxo Group Limited Triazole derivatives as modulators of dopamine d3 receptors
GB0517187D0 (en) * 2005-08-22 2005-09-28 Glaxo Group Ltd Compounds
AR060237A1 (es) * 2006-04-03 2008-06-04 Glaxo Group Ltd Compuesto de 3-azabiciclo[3.1.0]hexano como moduladores del receptor de dopamina d3, su uso para la preparacion de un medicamento para el tratamiento de afecciones psicoticas y composicion farmaceutica que lo comprende.
GB0616574D0 (en) * 2006-08-21 2006-09-27 Glaxo Group Ltd Compounds

Also Published As

Publication number Publication date
EP2070922A1 (en) 2009-06-17
EP2060570B1 (en) 2012-01-25
HK1103016A1 (en) 2007-12-14
HRP20100114T1 (hr) 2010-04-30
PL1745040T3 (pl) 2010-05-31
DE602005018190D1 (de) 2010-01-21
CA2557115A1 (en) 2005-09-01
EP1745040B1 (en) 2009-12-09
CN1946714A (zh) 2007-04-11
CY1112011T1 (el) 2015-11-04
RU2434011C2 (ru) 2011-11-20
EP2060570A2 (en) 2009-05-20
JP2007523208A (ja) 2007-08-16
DK2070922T3 (da) 2011-11-28
PT2070922E (pt) 2011-11-24
WO2005080382A1 (en) 2005-09-01
EP2070922B1 (en) 2011-08-17
RU2006133909A (ru) 2008-03-27
ATE520686T1 (de) 2011-09-15
ES2380990T3 (es) 2012-05-22
ATE451364T1 (de) 2009-12-15
DK1745040T3 (da) 2010-04-12
PT1745040E (pt) 2010-03-08
US20070142438A1 (en) 2007-06-21
PT2060570E (pt) 2012-05-07
AU2009212887A1 (en) 2009-09-24
CA2557115C (en) 2012-10-02
EP2060570A3 (en) 2009-06-03
HRP20110781T1 (hr) 2011-11-30
SI2070922T1 (sl) 2011-12-30
ES2337590T3 (es) 2010-04-27
SI1745040T1 (sl) 2010-04-30
TW200538113A (en) 2005-12-01
AU2005215918B2 (en) 2009-06-11
KR101143718B1 (ko) 2012-07-05
PL2060570T3 (pl) 2012-06-29
US8283474B2 (en) 2012-10-09
EP1745040A1 (en) 2007-01-24
PE20051173A1 (es) 2006-02-14
HRP20120281T1 (hr) 2012-04-30
AR047890A1 (es) 2006-03-01
AU2005215918A1 (en) 2005-09-01
US20100160336A1 (en) 2010-06-24
MA28438B1 (fr) 2007-02-01
IL177184A0 (en) 2006-12-10
BRPI0507945A (pt) 2007-07-24
ATE542816T1 (de) 2012-02-15
NO20064309L (no) 2006-11-23
JP4960217B2 (ja) 2012-06-27
SI2060570T1 (sl) 2012-05-31
AU2005215918C1 (en) 2010-01-21
DK2060570T3 (da) 2012-04-30
EP1745040B9 (en) 2010-06-02
US7855298B2 (en) 2010-12-21
US20100152195A1 (en) 2010-06-17
US8263782B2 (en) 2012-09-11
KR20060127991A (ko) 2006-12-13
CY1113029T1 (el) 2016-04-13
PL2070922T3 (pl) 2012-01-31
CY1109854T1 (el) 2014-09-10

Similar Documents

Publication Publication Date Title
CN1946714B (zh) 用作多巴胺d3受体调节剂的氮杂二环(3.1.0)己烷衍生物
CN105764902B (zh) 作为色氨酸羟化酶抑制剂的螺环化合物
CN110582495B (zh) 作为tnf活性的调节剂的稠合五环咪唑衍生物
AU2021200164B2 (en) Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
ES2465971T3 (es) Inhibidores de quinasa y método para tratar cáncer con los mismos
CN102414206B (zh) 异*唑-吡啶衍生物
CN112312904A (zh) 螺环化合物
US20230348386A1 (en) 3-phosphoglycerate dehydrogenase inhibitors and uses thereof
UA128332C2 (uk) Похідні конденсованих піразинів як інгібітори a2a/a2b
MX2015001892A (es) Analogos de piridazina 1,4-disustituida y metodos para el tratamiento de condiciones relacionadas con la deficiencia de smn.
CN102036955B (zh) 脱乙酰酶b的异羟肟酸盐为基础的抑制剂
CN102378762A (zh) 丙型肝炎病毒抑制剂
CN102459268A (zh) 二氮杂高金刚烷衍生物和其使用方法
CN112601749A (zh) 用于治疗认知损害的苯并二氮杂环庚三烯衍生物，组合物和方法
CN102036967A (zh) 作为5-ht6拮抗剂的芳基磺酰基吡唑啉甲脒衍生物
CA3047684A1 (en) Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
CN102164927A (zh) 用作多巴胺d3受体调节剂的异唑并[4,5]吡啶-3-基-哌嗪衍生物
PT88777B (pt) Processo para a preparacao de tetralinas, cromanos e compostos relacionados, substituidos, uteis no tratamento de asma, artrite e doencas relacionadas
CN102153547A (zh) 含有并环的噁唑烷酮抗菌素
JP5231992B2 (ja) ドーパミンｄ３受容体のモジュレーターとして有用なアザビシクロ（３．１．０）ヘキサン誘導体
CN104418842B (zh) 取代的吲哚化合物及其使用方法和用途
US20130018064A1 (en) Amino Heteroaryl Compounds as Beta-Secretase Modulators and Methods of Use
CN108884093A (zh) 6,7,8,9-四氢-5H-吡啶并[2,3-d]氮杂*多巴胺D3配体
TW202102511A (zh) 噻吩并雜環類衍生物、其製備方法及其在醫藥上的應用
CN106749219A (zh) 一种内酰胺类衍生物及其应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20110615

Termination date: 20170221